Cochlear, an implantable hearing solutions developer, has received clearance from the US Food and Drug Administration (FDA) to expand the use of its Osia System to children as young as five years old.
This decision lowers the eligible age from 12 years to five, allowing younger children with conductive hearing loss, mixed hearing loss, and single-sided sensorineural deafness (SSD) to benefit from the technology.
The Osia System represents a new category of bone conduction hearing solutions. It employs digital piezoelectric stimulation to bypass damaged areas of the natural hearing system and directly send sound vibrations to the inner ear.
